Xintela AB (publ)
STO: XINT.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Evy Lundgren-Åkerlund Assoc.Prof
- Employees
- 21
- Headquarters
- Lund, Sweden
- IPO year
- 2016
- Market cap
- SEK 167.4M
- Website
- https://www.xintela.se
Loading XINT…
Loading profile data…Frequently asked questions about XINT
What does Xintela AB (publ) (XINT.ST) do?
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem c...
Where does XINT.ST trade?
Xintela AB (publ) (XINT.ST) trades on the Stockholm Stock Exchange.
What sector is XINT.ST in?
Xintela AB (publ) (XINT.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xintela AB (publ)?
Evy Lundgren-Åkerlund Assoc.Prof is the chief executive officer of Xintela AB (publ) (XINT.ST).
Where is Xintela AB (publ) headquartered?
Xintela AB (publ) is headquartered in Sweden.
Does XINT.ST pay a dividend?
Xintela AB (publ) (XINT.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XINT.ST go public?
Xintela AB (publ) (XINT.ST) completed its initial public offering in 2016.